Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Spaner DE, McCaw L, Wang G, Tsui H, Shi Y.

Cancer Med. 2019 Apr;8(4):1540-1550. doi: 10.1002/cam4.2042. Epub 2019 Mar 7.

2.

Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis.

Liu T, Xia L, Yao Y, Yan C, Fan Y, Gajendran B, Yang J, Li YJ, Chen J, Filmus J, Spaner DE, Zacksenhaus E, Hao X, Ben-David Y.

Cell Death Dis. 2019 Feb 11;10(2):117. doi: 10.1038/s41419-019-1363-1.

3.

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

Shi Y, Wang G, Muhowski EM, McCaw L, Wang C, Bjarnason G, Woyach JA, Spaner DE.

Leukemia. 2019 Jul;33(7):1650-1662. doi: 10.1038/s41375-019-0381-4. Epub 2019 Jan 29.

PMID:
30696950
4.

Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.

Spaner DE, Venema R, Huang J, Norris P, Lazarus A, Wang G, Shi Y.

EBioMedicine. 2018 Sep;35:222-232. doi: 10.1016/j.ebiom.2018.08.045. Epub 2018 Aug 30.

5.

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.

Zhu F, McCaw L, Spaner DE, Gorczynski RM.

Leuk Res. 2018 Mar;66:28-38. doi: 10.1016/j.leukres.2018.01.006. Epub 2018 Jan 17.

PMID:
29353760
6.

PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.

Sun L, Shi Y, Wang G, Wang X, Zeng S, Dunn SE, Fairn GD, Li YJ, Spaner DE.

Leukemia. 2018 Jan;32(1):184-193. doi: 10.1038/leu.2017.162. Epub 2017 May 30.

PMID:
28555083
7.

PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.

Li YJ, Sun L, Shi Y, Wang G, Wang X, Dunn SE, Iorio C, Screaton RA, Spaner DE.

Leukemia. 2017 Sep;31(9):1905-1914. doi: 10.1038/leu.2016.395. Epub 2017 Jan 4.

PMID:
28050012
8.

Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.

McCaw L, Shi Y, Wang G, Li YJ, Spaner DE.

EBioMedicine. 2017 Feb;15:24-35. doi: 10.1016/j.ebiom.2016.11.033. Epub 2016 Nov 30.

9.

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.

Oppermann S, Lam AJ, Tung S, Shi Y, McCaw L, Wang G, Ylanko J, Leber B, Andrews D, Spaner DE.

Oncotarget. 2016 Nov 8;7(45):72608-72621. doi: 10.18632/oncotarget.11618.

10.

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM, Zúñiga-Pflücker JC, Leber B, Spaner DE, Andrews DW.

Blood. 2016 Aug 18;128(7):934-47. doi: 10.1182/blood-2015-12-687814. Epub 2016 Jun 13.

11.

PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions.

Wang X, Wang G, Shi Y, Sun L, Gorczynski R, Li YJ, Xu Z, Spaner DE.

Oncogenesis. 2016 Jun 6;5(6):e232. doi: 10.1038/oncsis.2016.41.

12.

Characterization of CD200 Ectodomain Shedding.

Wong KK, Zhu F, Khatri I, Huo Q, Spaner DE, Gorczynski RM.

PLoS One. 2016 Apr 25;11(4):e0152073. doi: 10.1371/journal.pone.0152073. eCollection 2016.

13.

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Spaner DE, Wang G, McCaw L, Li Y, Disperati P, Cussen MA, Shi Y.

Haematologica. 2016 May;101(5):e192-5. doi: 10.3324/haematol.2015.135418. Epub 2016 Jan 27. No abstract available.

14.

A link between hypercholesterolemia and chronic lymphocytic leukemia.

Chow S, Buckstein R, Spaner DE.

Leuk Lymphoma. 2016;57(4):797-802. doi: 10.3109/10428194.2015.1088651. Epub 2015 Oct 9.

PMID:
26325342
15.

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

Li Y, Shi Y, McCaw L, Li YJ, Zhu F, Gorczynski R, Duncan GS, Yang B, Ben-David Y, Spaner DE.

Blood. 2015 Aug 6;126(6):766-78. doi: 10.1182/blood-2014-12-618678. Epub 2015 Jun 3.

PMID:
26041742
16.

Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.

Berinstein NL, Bhella S, Pennell NM, Cheung MC, Imrie KR, Spaner DE, Milliken V, Zhang L, Hewitt K, Boudreau A, Reis MD, Chesney A, Good D, Ghorab Z, Hicks LK, Piliotis E, Buckstein R.

Ann Hematol. 2015 May;94(5):813-23. doi: 10.1007/s00277-014-2288-5. Epub 2015 Jan 8.

PMID:
25567231
17.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

18.

A role for oleoylethanolamide in chronic lymphocytic leukemia.

Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia RB, Baccei C, Prasit P, Spaner DE.

Leukemia. 2014 Jul;28(7):1381-7. doi: 10.1038/leu.2014.10. Epub 2014 Jan 13.

PMID:
24413323
19.

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia.

Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC, Minden M, Blechert AK, Genzel Y, Reichl U, Spaner DE.

Blood. 2013 Aug 8;122(6):969-80. doi: 10.1182/blood-2013-03-489468. Epub 2013 Jun 27.

PMID:
23814018
20.

Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia.

Haeri M, Li Y, Li Y, Li Q, Spaner DE, Ben-David Y.

Int J Oncol. 2013 Jul;43(1):169-76. doi: 10.3892/ijo.2013.1943. Epub 2013 May 16.

PMID:
23677281
21.

Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins.

Tomic J, McCaw L, Li Y, Hough MR, Ben-David Y, Moffat J, Spaner DE.

Exp Hematol. 2013 Aug;41(8):675-86. doi: 10.1016/j.exphem.2013.04.004. Epub 2013 Apr 15.

PMID:
23597602
22.

Micromanaging a large tumor suppressor.

Li Y, Spaner DE.

Cell Cycle. 2012 Dec 15;11(24):4497. doi: 10.4161/cc.22935. Epub 2012 Dec 6. No abstract available.

23.

PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S, McCaw L, Wong K, Gary-Gouy H, Dalloul A, Ceddia R, Gorzcynski R.

Leukemia. 2013 Apr;27(5):1090-9. doi: 10.1038/leu.2012.329. Epub 2012 Nov 19.

PMID:
23160450
24.

Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice.

Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM.

Cancer Res. 2012 Oct 1;72(19):4931-43. doi: 10.1158/0008-5472.CAN-12-1390. Epub 2012 Aug 8.

25.

A role for Danazol in chronic lymphocytic leukemia.

Tung S, Spaner DE.

Leukemia. 2012 Jul;26(7):1684-6. doi: 10.1038/leu.2011.386. Epub 2012 Jan 13. No abstract available.

PMID:
22289992
26.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.

Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.

27.

Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.

Spaner DE.

Leukemia. 2012 May;26(5):1144-5. doi: 10.1038/leu.2011.329. Epub 2011 Nov 8. No abstract available.

PMID:
22064354
28.

Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.

Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA.

Gene Ther. 2011 Oct;18(10):986-95. doi: 10.1038/gt.2011.53. Epub 2011 Apr 14.

29.

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia.

Tomic J, Lichty B, Spaner DE.

Blood. 2011 Mar 3;117(9):2668-80. doi: 10.1182/blood-2010-05-285999. Epub 2011 Jan 4.

PMID:
21205928
30.

Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia.

Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R, Dennis JW, Williams R, Gross BJ, Walker S, Zuccolo J, Deans JP, Hart GW, Spaner DE.

Leukemia. 2010 Sep;24(9):1588-98. doi: 10.1038/leu.2010.152. Epub 2010 Jul 29.

31.

The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis.

Lakhanpal GK, Vecchiarelli-Federico LM, Li YJ, Cui JW, Bailey ML, Spaner DE, Dumont DJ, Barber DL, Ben-David Y.

Blood. 2010 Jul 22;116(3):428-36. doi: 10.1182/blood-2009-10-250217. Epub 2010 May 5.

PMID:
20445019
32.

The role of CD200 in immunity to B cell lymphoma.

Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM.

J Leukoc Biol. 2010 Aug;88(2):361-72. doi: 10.1189/jlb.1009686. Epub 2010 May 4.

PMID:
20442224
33.

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia.

Spaner DE, Shi Y, White D, Shaha S, He L, Masellis A, Wong K, Gorczynski R.

Leukemia. 2010 Jan;24(1):222-6. doi: 10.1038/leu.2009.195. Epub 2009 Sep 17. No abstract available.

PMID:
19759558
34.

Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells.

Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW, Spaner DE.

Clin Exp Immunol. 2009 Nov;158(2):186-98. doi: 10.1111/j.1365-2249.2009.04003.x. Epub 2009 Jul 17.

35.

Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype.

Romieu-Mourez R, François M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J.

J Immunol. 2009 Jun 15;182(12):7963-73. doi: 10.4049/jimmunol.0803864.

36.

The B-cell calcium sensor predicts progression of chronic lymphocytic leukemia.

Hammond CM, Shi Y, White D, Cervi D, Tomic J, Spaner DE.

Leukemia. 2009 Feb;23(2):426-9. doi: 10.1038/leu.2008.351. Epub 2008 Dec 11. No abstract available.

PMID:
19078991
37.

Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.

Spaner DE, Foley R, Galipeau J, Bramson J.

Oncogene. 2008 Jan 7;27(2):208-17. doi: 10.1038/sj.onc.1210905. Review.

PMID:
18176602
38.

Extracellular calcium sensing promotes human B-cell activation and function.

Hammond CM, White D, Tomic J, Shi Y, Spaner DE.

Blood. 2007 Dec 1;110(12):3985-95. Epub 2007 Aug 27.

PMID:
17724142
39.

Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.

Shi Y, White D, He L, Miller RL, Spaner DE.

Cancer Res. 2007 Feb 15;67(4):1823-31.

40.

Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.

Spaner DE, Masellis A.

Leukemia. 2007 Jan;21(1):53-60. Epub 2006 Oct 26. Review.

PMID:
17066089
41.

Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.

Tomic J, White D, Shi Y, Mena J, Hammond C, He L, Miller RL, Spaner DE.

J Immunol. 2006 Mar 15;176(6):3830-9.

42.

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.

Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, Verma S, Iscoe N, Hamilton P, Berinstein NL.

Cancer. 2006 Feb 15;106(4):890-9.

43.

Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.

Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, Radvanyi L.

Leukemia. 2006 Feb;20(2):286-95.

PMID:
16341037
44.

Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod.

Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y.

Leuk Lymphoma. 2005 Jun;46(6):935-9.

PMID:
16019542
45.

A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.

Spaner DE, Hammond C, Mena J, Foden C, Deabreu A.

Cancer Immunol Immunother. 2005 Jul;54(7):635-46. Epub 2004 Dec 17.

PMID:
15918075
46.

Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells.

Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L, Millar AE, Debenedette M, Schuh AC, Baryza JL, Wender PA, Radvanyi L, Spaner DE.

J Immunother. 2005 Jan-Feb;28(1):28-39.

PMID:
15614042
47.
48.

Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells.

Spaner DE.

J Leukoc Biol. 2004 Aug;76(2):338-51. Epub 2004 Apr 23. Review.

PMID:
15277580
49.

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.

Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE.

Clin Cancer Res. 2003 Oct 1;9(12):4347-55.

50.

Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K, Spaner DE.

Clin Cancer Res. 2003 May;9(5):1656-65.

Supplemental Content

Loading ...
Support Center